Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist, and Executive Director of Employer Services at the City of Hope Comprehensive Cancer Center in Duarte, CA.

When Do Recurrences of Lung Cancer Happen After Surgery?
Fri, 08/19/2011 - 08:56
Author
Howard (Jack) West, MD, Associate Clinical Professor, Medical Oncology, Executive Director, Employer Services, Founder, President and CEO of GRACE

The answer is, "Usually pretty early". I tell my patients that the risk is "front-loaded", meaning that we typically see recurrences occur in the first couple of years after curative therapy for lung cancer, if they're going to happen at all. That said, I haven't seen a lot of data that actually illustrates the point, but there was a presentation at ASCO this past year that addressed how well recurrences/disease-free survival predict overall survival after surgery for resectable NSCLC. Not surprisingly, there was a very good correlation, though it wasn't perfect (patients can die from side effects of the treatment, or from unrelated but competing medical problems).

In the process of reviewing the data from two "meta-analyses" of multiple smaller studies of chemotherapy after surgery, either with or without radiation also administered, a group led by Dr. Michiels from Institute Gustave-Roussy in Villejuif, France reported on the "lead time" that diseease-free survival gives in predicting overall survival. They found that, if recurrences were going to ever happen, about 50% occurred within the first year, at least two-thirds within two years, and about 80% or more within three years.

time-to-recurrence-in-early-stage-nsclc (click on image to enlarge)

This really corroborates the experience of clinicians caring for patients after surgery. Once you get out 2-3 years after surgery, odds are decidedly in your favor, with declining risk of ever seeing a recurrence if it hasn't happened within that time. Though the authors didn't report on the data with greater specificity, I strongly suspect that the data would show that patients with higher stage disease (stages II and III, for instance) are even more likely to recur early or not at all, while those with stage I NSCLC, especially those with smaller tumors or with cancers that we'd anticipate having more indolent behavior (bronchioloalveolar carcinoma, for instance) still having a risk that stretches out for years.

I don't think I've seen a similar analysis of patients with locally advanced NSCLC treated with chemo/radiation, but we see the same trend of front-loaded risk there too. Almost always focusing on patients with a higher stage than resected NSCLC trials, these studies show a median DFS of about 10 months, while others are dropping out from significant side effects and even a 5-7% treatment-related death rate in the more aggressive chemo/radiation trials (and these are in more selected patients than the broader population in the real world, many of whom wouldn't be eligible for such trials). A just-published trial of new non-surgical strategies for stage III NSCLC used OS 18 months after enrollment/start of treatment as the predictor of the efficacy of the strategy.

Clearly, the take-home message is that the risk of recurrence/progression for most patients with potentially curable lung cancer -- and this applies to limited disease small cell lung cancer as well -- is primarily focused in the first 12-24 months, diminishing thereafter. How early the peak risk is, and how long the tail of recurrence risk goes out, is largely related to the aggressiveness of the underlying cancer.

Next Previous link

Previous PostNext Post

Related Content

Image
Mandarin LCVL
Video
王林医生用普通话讨论重要的肺癌信息。这些信息包括靶向治疗、晚期疾病的症状、循环肿瘤 DNA、治疗方案等。我们鼓励您与社区中说普通话的人分享。 Dr. Lin Wang discusses important lung cancer information in Mandarin. This information includes targeted therapy, symptoms of advanced disease, circulating tumor DNA, treatment options, and more. We encourage you to share this with the Mandarin speakers in your community. To watch the complete Playlist visit: https://www.youtube.com/playlist?list=PLWsyUmdjLXhGnSxobmz4CBP3pxAj7nDa…;  
Image
Tell your story!  Apply now for the Clinical Trials Experiences through Storytelling Program
Article
We are excited to launch our third year of this program; tell your story and help us help others! Apply Online Now!     GRACE Patient Perspectives: Clinical Trials Experiences Storytelling Program Overview  
Image
Blood Cancer OncTalk
Video
Blood Cancer OncTalk was a live presentation that brought together top oncologists to discuss emerging concepts and treatment options in blood cancer. The program was chaired by Dr. Aaron Goodman, with the participation of Dr. Mazie Tsang, Hematologist / Oncologist; Dr. Autumn Jeong, Hematologist / Oncologist; Dr. Shaji Kumar, Hematologist / Oncologist; and Dr. Sridevi Rajeeve, Hematologist / Oncologist.

Forum Discussions

Hi Caregiver and welcome to Grace.  I'm sorry that you need to be here and hope we can help.  Osimertinib has better efficacy than gefitinib (including OS and reaching the brain)...

Hi Bob, Welcome to Grace.  I'm sorry about your sil.  Unfortunately, cancer becomes resistant to TKIs like tagrisso.  Sometimes all of the cancer becomes resistant at once and sometimes just parts...

Recent Comments

JOIN THE CONVERSATION
Hi Tammy,  Welome to Grace. …
By JanineT GRACE … on Tue, 05/16/2023 - 13:44
Concerned
By Tndiuka10 on Fri, 05/12/2023 - 21:13
Hi Caregiver and welcome to…
By JanineT GRACE … on Fri, 05/12/2023 - 14:20
Hi Bob, Welcome to Grace.  I…
By JanineT GRACE … on Tue, 05/02/2023 - 12:29